| Name | Title | Contact Details |
|---|
Why we`re excited: The mission for Payformance Solutions is simple. We aim to be a catalyst for payment transformation in the healthcare industry. Our proprietary software solutions allow payers and providers to focus on what really matters: providing patients with access to care that yields the best health outcomes, at the lowest costs. The healthcare industry is complex and fragmented. Payers and providers are faced with a lack of transparency and conflicting financial goals that fail to consider the health outcomes of patients. Payformance offers data-driven, turnkey software solutions that provide payers and providers with the technical tools and resources needed to design, evaluate, build, measure, and negotiate value-based reimbursement contracts — as a neutral third party. Our holistic solutions allow payers and providers to collaborate in an ecosystem that aligns financial goals with patient outcomes. Not to boast, but a little bit about us: Payformance Solutions is a health-tech company dedicated to advancing payment transformation in the healthcare industry. We are a wholly owned subsidiary of Altarum Institute, a nonprofit systems research and consulting organization that has been servicing government and private sector clients since 1946. Altarum Institute, as a non-profit, ensures that the public interest is always preeminent in client work. Our dedication to social responsibility is evident in all that we do, serving the public good with integrity and enabling others to do the same. Altarum develops and promotes best practices in the application of information technology to health and health care. Applying systems research principles and analytic objectivity, we work to increase access to health information; improve the organization and usability of health information; and develop new knowledge from health information.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
Mediprobe Research Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kaiser Permanente Washington Health Research Institute (KPWHRI) is a non-profit research organization that conducts practical research to improve the health and health care of Kaiser Permanente members and the public.
Catholic Health Association of the United States CHA is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.